RA Capital Healthcare Fund LP's Form 4 filing
Jade Biosciences, Inc. (JBIO) · filed Jul 6, 2021
- Accession no.
- 0001104659-21-089472
- Filed
- Jul 6, 2021, 5:03 PM ET
- Trade date
- Jul 2, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 4 derivative transactions. Open-market purchases total $39.0M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| RA Capital Healthcare Fund LPCIK 0001315082 | Director, 10% Owner |
| Ra Capital Management, L.P.CIK 0001346824 | Director, 10% Owner |
| Kolchinsky PeterCIK 0001384859 | Director, 10% Owner |
| Shah Rajeev M.CIK 0001619841 | Director, 10% Owner |
| RA Capital Nexus Fund, L.P.CIK 0001780117 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 2, 2021 | Common Stock | CConversionAcquired | +3,938,387 | –F1 | – | 4,179,854 | Indirect | |
| Jul 2, 2021 | Common Stock | PPurchaseAcquired | +2,785,714 | $14.00 | +$38,999,996 | 6,965,568 | Indirect | |
| Jul 2, 2021 | Common Stock | CConversionAcquired | +987,244 | –F1 | – | 987,244 | Indirect | |
| Jul 2, 2021 | Common Stock | CConversionAcquired | +311,170 | –F1 | – | 311,170 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 2, 2021 | Common Stock | CConversionDisposed | −1,287,825 | $0.00 | $0 | 0 | Indirect | |
| Jul 2, 2021 | Common Stock | CConversionDisposed | −2,650,562 | $0.00 | $0 | 0 | Indirect | |
| Jul 2, 2021 | Common Stock | CConversionDisposed | −987,244 | $0.00 | $0 | 0 | Indirect | |
| Jul 2, 2021 | Common Stock | CConversionDisposed | −311,170 | $0.00 | $0 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On July 2, 2021, each share of Series Seed Preferred Stock and Series A Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-3.1060103 basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
Referenced by the price of 3 transactions in Table I.